Bayer vs. Dr. Reddy’s: Finerenone Patent Dismissal Analysis in Landmark Pharma Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Bayer AG v. Dr. Reddy’s Laboratories, Ltd. |
| Case Number | 1:25-cv-16901 |
| Court | District of New Jersey |
| Duration | Oct 2025 – Feb 2026 105 days |
| Outcome | Voluntary Dismissal without Prejudice |
| Patents at Issue | |
| Accused Products | KERENDIA® (finerenone) tablets |
Case Overview
The Parties
⚖️ Plaintiff
A global life sciences and pharmaceutical leader headquartered in Germany, with significant U.S. operations. Holder of the KERENDIA® (finerenone) franchise.
🛡️ Defendant
A major Indian multinational generic pharmaceutical manufacturer with extensive Abbreviated New Drug Application (ANDA) filing activity in the U.S.
The Patent at Issue
This litigation centered on **U.S. Reissue Patent No. RE49,826** (corrected application number US17/367,066). Reissue patents are notable because they undergo re-examination at the USPTO to correct errors in originally granted patents, potentially broadening or clarifying claim scope.
- • US RE49,826 — Claims covering KERENDIA® (finerenone) composition or formulation.
Developing a similar pharmaceutical product?
Check if your drug formulation might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
On **February 6, 2026**, Bayer AG filed a voluntary dismissal of **all claims without prejudice** pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i). Each party agreed to bear its own attorneys’ fees and costs. No damages were awarded, no injunctive relief was granted, and no judicial findings on the merits were issued.
Key Legal Issues
The case was a standard **pharmaceutical patent infringement action** under the Hatch-Waxman Act, initiated after Dr. Reddy’s filed an ANDA with a Paragraph IV certification. However, the voluntary dismissal occurred before any substantive motions were adjudicated, meaning there are no judicial findings regarding claim construction, validity challenges, or infringement analysis of RE49,826. The dismissal without prejudice preserves Bayer’s right to re-file its claims in the future, often signaling a confidential settlement or licensing agreement outside the courtroom.
Freedom to Operate (FTO) Analysis: Finerenone
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in the finerenone space
- See which companies are most active in MRA drug patents
- Understand claim construction patterns for reissue patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your drug formulation or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Area
Mineralocorticoid Receptor Antagonist (MRA) compounds
25+ Related Patents
In MRA drug space
Formulation Design-Around Options
Available for some claims
✅ Key Takeaways
Rule 41(a)(1)(A)(i) dismissals in Hatch-Waxman cases frequently signal confidential licensing settlements — monitor for subsequent re-filing activity or market launch disclosures.
Search related case law →Reissue patents introduce prosecution history complexity that can affect claim construction strategy in ANDA litigation.
Explore precedents →Frequently Asked Questions
The case involved U.S. Reissue Patent No. RE49,826 (application number US17/367,066) relating to KERENDIA® (finerenone) tablets in 10 mg, 20 mg, and 40 mg dosages.
Bayer voluntarily dismissed all claims without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(i) on February 6, 2026. No specific reason was stated publicly; the structure is consistent with a negotiated settlement or licensing arrangement.
Because the dismissal was without prejudice, Bayer retains full rights to re-assert RE49,826. The patent’s validity and claim scope were not adjudicated, leaving open significant legal questions for future proceedings.
Ready to Navigate Complex Pharma Patent Litigation?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER (Public Access to Court Electronic Records) — Case 1:25-cv-16901
- USPTO Patent Center — U.S. Reissue Patent No. RE49,826
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 41(a)(1)(A)(i)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.